Wall Street analysts predict that Tenax Therapeutics Inc (NASDAQ:TENX) will post earnings per share of ($0.45) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tenax Therapeutics’ earnings. Tenax Therapeutics posted earnings of ($1.29) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 65.1%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 13th.

On average, analysts expect that Tenax Therapeutics will report full year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.64) to ($1.26). For the next fiscal year, analysts expect that the business will report earnings of ($1.06) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Tenax Therapeutics.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter.

Separately, ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st.

A hedge fund recently bought a new stake in Tenax Therapeutics stock. Bank of New York Mellon Corp acquired a new position in Tenax Therapeutics Inc (NASDAQ:TENX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,077 shares of the specialty pharmaceutical company’s stock, valued at approximately $46,000. Bank of New York Mellon Corp owned approximately 2.59% of Tenax Therapeutics as of its most recent SEC filing. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:TENX traded up $0.03 during trading on Wednesday, reaching $1.42. The stock had a trading volume of 3,325 shares, compared to its average volume of 68,367. The firm’s fifty day moving average is $1.34. The company has a current ratio of 11.04, a quick ratio of 11.04 and a debt-to-equity ratio of 0.01. The firm has a market cap of $8.61 million, a PE ratio of -0.16 and a beta of 1.42. Tenax Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.94.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.

Further Reading: Support Level

Get a free copy of the Zacks research report on Tenax Therapeutics (TENX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.